

- Eskelin S, Pyrhonen S, Summanen P, et al. Screening for metastatic malignant melanoma of the uvea revisited. *Cancer* 1999;85:1151–1159.
- Diener-West M, Reynolds SM, Agugliaro DJ, et al. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. *J Clin Oncol* 2004;22:2438–2444.
- Freton A, Pavlick AC, Finger PT. Systemic evaluation and management of patients with uveal melanoma. In: Ryan SJ, Schachar AP, ed. *RETINA*. Vol III. London: Elsevier-Saunders; 2013:2313–2315.
- Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. *Arch Ophthalmol* 2006;124:1684–1693.
- American Brachytherapy Society—Ophthalmic Oncology Task Force. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. *Brachytherapy* 2014;13:1–14.
- Finger PT. Anti-VEGF bevacizumab (Avastin) for radiation optic neuropathy. *Am J Ophthalmol* 2007;143:335–338.
- Finger PT, Chin K. Anti-vascular endothelial growth factor bevacizumab (avastin) for radiation retinopathy. *Arch Ophthalmol* 2007;125:751–756.
- Finger PT, Chin KJ. Intravitreal ranibizumab (lucentis) for radiation maculopathy. *Arch Ophthalmol* 2010;128:249–252.
- Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. *Ophthalmol Clin North Am* 2005;18:75–84, viii.
- Hu DN, Yu GP, McCormick SA, et al. Population-based incidence of uveal melanoma in various races and ethnic groups. *Am J Ophthalmol* 2005;140:612–617.
- Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973–1997. *Ophthalmology* 2003;110:956–961.
- Inskip PD, Devesa SS, Fraumeni JF Jr. Trends in the incidence of ocular melanoma in the United States, 1974–1998. *Cancer Causes Control* 2003;14:251–257.
- Hawkins BS, Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. *Am J Ophthalmol* 2004;138:936–951.
- Roy PE, Schaeffer EM. Nevus of Ota and choroidal melanoma. *Surv Ophthalmol* 1967;12:130–140.
- Horn EP, Hartge P, Shields JA, et al. Sunlight and risk of uveal melanoma. *J Natl Cancer Inst* 1994;86:1476–1478.
- Khan S, Finger PT, Yu GP, et al. Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study. *Arch Ophthalmol* 2012;130:57–64.
- Harbour JW. The genetics of uveal melanoma: an emerging framework for targeted therapy. *Pigment Cell Melanoma Res* 2012;25:171–181.
- Barker-Griffith AE, Streeten BW. Familial uveal melanoma: a report of four cases in two families and literature review. *Can J Ophthalmol* 2004;39:403–408.
- Kivela T, Kujala E. Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond. *Eye (Lond)* 2013;27:243–252.
- Newman H, Chin KJ, Finger PT. Subfoveal choroidal melanoma: pretreatment characteristics and response to plaque radiation therapy. *Arch Ophthalmol* 2011;129:892–898.
- Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. *Am J Ophthalmol* 1998;125:745–766.
- Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS report no. 1. *Arch Ophthalmol* 1990;108:1268–1273.
- Albert DM, Ruzzo MA, McLaughlin MA, et al. Establishment of cell lines of uveal melanoma. Methodology and characteristics. *Invest Ophthalmol Vis Sci* 1984;25:1284–1299.
- Seddon JM, Polivogianis L, Hsieh CC, et al. Death from uveal melanoma. Number of epithelioid cells and inverse SD of nucleolar area as prognostic factors. *Arch Ophthalmol* 1987;105:801–806.
- Marigo FA, Finger PT, McCormick SA, et al. Iris and ciliary body melanomas: ultrasound biomicroscopy with histopathologic correlation. *Arch Ophthalmol* 2000;118:1515–1521.
- Radcliffe NM, Finger PT. Eye cancer related glaucoma: current concepts. *Surv Ophthalmol* 2009;54:47–73.
- Collaborative Ocular Melanoma Study Group, Boldt HC, Byrne SF, et al. Baseline echographic characteristics of tumors in eyes of patients enrolled in the Collaborative Ocular Melanoma Study: COMS report no. 29. *Ophthalmology* 2008;115:1390–1397, 1397.e1–e2.
- Lavinsky D, Belfort RN, Navajas E, et al. Fundus autofluorescence of choroidal nevus and melanoma. *Br J Ophthalmol* 2007;91:1299–1302.
- Finger PT, Reddy S, Chin K. High-frequency ultrasound characteristics of 24 iris and iridociliary melanomas: before and after plaque brachytherapy. *Arch Ophthalmol* 2007;125:1051–1058.
- Augsburger JJ, Shields JA. Fine needle aspiration biopsy of solid intraocular tumors: indications, instrumentation and techniques. *Ophthalmic Surg* 1984;15:34–40.
- McCannel TA, Chang MY, Burgess BL. Multi-year follow-up of fine-needle aspiration biopsy in choroidal melanoma. *Ophthalmology* 2012;119:606–610.
- Finger PT, 7th Edition, AJCC-UICC. Ophthalmic Oncology Task Force. The 7th edition AJCC staging system for eye cancer: an international language for ophthalmic oncology. *Arch Pathol Lab Med* 2009;133:1197–1198.
- The 7th Edition AJCC-OOTF. Malignant melanoma of the uvea. In: Edge SE, Byrd DR, Compton CA, Fritz AG, et al., ed. *AJCC Cancer Staging Manual*. Vol X. 7th ed. New York, NY: Springer; 2009:547–559.
- Shields CL, Kaliki S, Furuta M, et al. American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients. *Ophthalmology* 2013;120:2066–2071.
- Chiu-Tsao ST, Astrahan MA, Finger PT, et al. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS. *Med Phys* 2012;39:6161–6184.
- Finger PT. Do you speak ocular tumor? *Ophthalmology* 2003;110:13–14.
- Finger PT, Chin KJ, Duvall G, et al. Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients. *Ophthalmology* 2009;116:790–796, 796.e1.
- Kujala E, Damato B, Coupland SE, et al. Staging of ciliary body and choroidal melanomas based on anatomic extent. *J Clin Oncol* 2013;31:2825–2831.
- Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. *Arch Ophthalmol* 2005;123:1639–1643.
- Semenova E, Finger PT. Palladium-103 radiation therapy for small choroidal melanoma. *Ophthalmology* 2013;120:2353–2357.
- Finger PT, Chin KJ. Antivascular endothelial growth factor bevacizumab for radiation optic neuropathy: secondary to plaque radiotherapy. *Int J Radiat Oncol Biol Phys* 2012;82:789–798.
- Melia BM, Abramson DH, Albert DM, et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. *Ophthalmology* 2001;108:348–366.
- Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. *Ophthalmology* 2002;109:2197–2206.
- Packer S, Stoller S, Lesser ML, et al. Long-term results of iodine 125 irradiation of uveal melanoma. *Ophthalmology* 1992;99:767–773, discussion 774.
- Fontanesi J, Meyer D, Xu S, et al. Treatment of choroidal melanoma with I-125 plaque. *Int J Radiat Oncol Biol Phys* 1993;26:619–623.
- Lommatzsch PK. beta-Irradiation of choroidal melanoma with 106Ru/106Rh applicators. 16 years' experience. *Arch Ophthalmol* 1983;101:713–717.
- Char DH, Kroll SM, Castro J. Ten-year follow-up of helium ion therapy for uveal melanoma. *Am J Ophthalmol* 1998;125:81–89.
- Brovkina AF, Zarubei GD. Ciliochoroidal melanomas treated with a narrow medical proton beam. *Arch Ophthalmol* 1986;104:402–404.
- Gragoudas ES, Seddon JM, Egan K, et al. Long-term results of proton beam irradiated uveal melanomas. *Ophthalmology* 1987;94:349–353.
- Rivard MJ, Chiu-Tsao ST, Finger PT, et al. Comparison of dose calculation methods for brachytherapy of intraocular tumors. *Med Phys* 2011;38:306–316.
- Finger PT, Chin KJ, Yu GP, et al. Risk factors for radiation maculopathy after ophthalmic plaque radiation for choroidal melanoma. *Am J Ophthalmol* 2010;149:608–615.
- Milman T, Petousis V, McCormick SA, et al. Anterior segment tumor aspiration cutter-assisted biopsy: experience with pathology. *Am J Ophthalmol* 2011;152:776–783.e1.
- Yousef YA, Finger PT. Lack of radiation maculopathy after palladium-103 plaque radiotherapy for iris melanoma. *Int J Radiat Oncol Biol Phys* 2012;83:1107–1112.
- Finger PT. Radiation therapy for choroidal melanoma. *Surv Ophthalmol* 1997;42:215–232.
- Wilson MW, Hungerford JL. Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. *Ophthalmology* 1999;106:1579–1587.
- Char DH, Quivey JM, Castro JR, et al. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. *Ophthalmology* 1993;100:1547–1554.
- Hungerford JL, Foss AJ, Whelahan I, et al. Side effects of photon and proton radiotherapy for ocular melanoma. *Front Radiat Ther Oncol* 1997;30:287–293.
- Shields CL, Naseripour M, Shields JA, et al. Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications. *Am J Ophthalmol* 2003;135:648–656.
- Finger PT. Plaque radiation therapy for malignant melanoma of the iris and ciliary body. *Am J Ophthalmol* 2001;132:328–335.
- Petousis V, Finger PT, Milman T. Multifocal iris melanoma treated with total anterior segment palladium-103 plaque radiation therapy. *Graefes Arch Clin Exp Ophthalmol* 2011;249:937–940.
- Garcia JP Jr, Garcia PT, Rosen RB, et al. A 3-dimensional ultrasound C-scan imaging technique for optic nerve measurements. *Ophthalmology* 2004;111:1238–1243.

62. Finger PT. Finger's "slotted" eye plaque for radiation therapy: treatment of juxtapapillary and circumpapillary intraocular tumours. *Br J Ophthalmol* 2007;91:891–894.
63. Finger PT, Chin KJ, Tena LB. A five-year study of slotted eye plaque radiation therapy for choroidal melanoma: near, touching, or surrounding the optic nerve. *Ophthalmology* 2012;119:415–422.
64. Finger PT, Tena LB, Semenova E, et al. Extrascleral extension of choroidal melanoma: Post-enucleation high-dose-rate interstitial brachytherapy of the orbit. *Brachytherapy* 2014;13:275–280.
65. Melia M, Moy CS, Reynolds SM, et al. Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3. *Arch Ophthalmol* 2006;124:226–238.
66. Finger PT, Chin KJ. High-dose (2.0 mg) intravitreal ranibizumab for recalcitrant radiation retinopathy. *Eur J Ophthalmol* 2013;23:850–856.
67. Finger PT, Kurli M, Reddy S, et al. Whole body PET/CT for initial staging of choroidal melanoma. *Br J Ophthalmol* 2005;89:1270–1274.
68. Fretton A, Chin KJ, Raut R, et al. Initial PET/CT staging for choroidal melanoma: AJCC correlation and second nonocular primaries in 333 patients. *Eur J Ophthalmol* 2012;22:236–243.
69. Kurli M, Reddy S, Tena LB, et al. Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma. *Am J Ophthalmol* 2005;140:193–199.
70. Chin K, Finger PT, Kurli M, et al. Second cancers discovered by (18)FDG PET/CT imaging for choroidal melanoma. *Optometry* 2007;78:396–401.
71. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Second primary cancers after enrollment in the COMS trials for treatment of choroidal melanoma: COMS Report No. 25. *Arch Ophthalmol* 2005;123:601–604.
72. Finger PT, Chin K, Iacob CE. 18-Fluorine-labelled 2-deoxy-2-fluoro-D-glucose positron emission tomography/computed tomography standardised uptake values: a non-invasive biomarker for the risk of metastasis from choroidal melanoma. *Br J Ophthalmol* 2006;90:1263–1266.
73. Finger PT, Chin KJ. [(18)F]Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) physiologic imaging of choroidal melanoma: before and after ophthalmic plaque radiation therapy. *Int J Radiat Oncol Biol Phys* 2011;79:137–142.
74. Damato B. Does ocular treatment of uveal melanoma influence survival? *Br J Cancer* 2010;103:285–290.
75. Kaiserman I, Anteby I, Chowers I, et al. Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma. *Br J Ophthalmol* 2004;88:892–895.
76. Bergman L, Nilsson B, Lundell G, et al. Ruthenium brachytherapy for uveal melanoma, 1979–2003: survival and functional outcomes in the Swedish population. *Ophthalmology* 2005;112:834–840.
77. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. *Invest Ophthalmol Vis Sci* 2003;44:4651–4659.
78. Saakyan SV, Panteleva OG, Shirina TV. Estimation of long-term survival in uveal melanoma after organ-preserving treatment and enucleation. *Russian Ophthalmological Journal* 2011;4:67–70.
79. Feldman ED, Pingpank JF, Alexander HR Jr. Regional treatment options for patients with ocular melanoma metastatic to the liver. *Ann Surg Oncol* 2004;11:290–297.
80. Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma. *Semin Oncol* 2010;37:127–138.
81. Helton WS. Ocular melanoma metastatic to the liver: the role of surgery in multimodality therapy. *Ann Surg Oncol* 2004;11:242–244.
82. Kolandjian NA, Wei C, Patel SP, et al. Delayed systemic recurrence of uveal melanoma. *Am J Clin Oncol* 2013;36:443–449.
83. Triozzi PL, Eng C, Singh AD. Targeted therapy for uveal melanoma. *Cancer Treat Rev* 2008;34:247–258.
84. Tsukahara S, Wakui K, Ohzeki S. Simultaneous bilateral primary diffuse malignant uveal melanoma: case report with pathological examination. *Br J Ophthalmol* 1986;70:33–38.
85. Milman T, Hu DN, McCormick SA, et al. Expression of neurotrophin receptors by retinoinvasive uveal melanoma. *Melanoma Res* 2012;22:164–168.
86. Makitie T, Summanen P, Tarkkanen A, et al. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. *Invest Ophthalmol Vis Sci* 2001;42:1414–1421.
87. Prescher G, Bornfeld N, Hirsche H, et al. Prognostic implications of monosomy 3 in uveal melanoma. *Lancet* 1996;347:1222–1225.
88. Coupland SE, Vorum H, Mandal N, et al. Proteomics of uveal melanomas suggests HSP-27 as a possible surrogate marker of chromosome 3 loss. *Invest Ophthalmol Vis Sci* 2010;51:12–20.
89. Sandinha MT, Farquharson MA, McKay IC, et al. Monosomy 3 predicts death but not time until death in choroidal melanoma. *Invest Ophthalmol Vis Sci* 2005;46:3497–3501.
90. Saakyan SV, Shirina TV. Dependence of survival rate on different treatments with uveal melanoma. *43rd Spring Meeting of the European Ophthalmic Oncology Group*. Ivalo, Finland, 2013:34.
91. Harbour JW. Molecular prognostic testing and individualized patient care in uveal melanoma. *Am J Ophthalmol* 2009;148:823–829.e1.
92. Brantley MA Jr, Harbour JW. Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region. *Cancer Res* 2000;60:4320–4323.
93. Ehlers JP, Worley L, Onken MD, et al. DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma. *Clin Cancer Res* 2005;11:3609–3613.
94. Lake SL, Damato BE, Kalirai H, et al. Single nucleotide polymorphism array analysis of uveal melanomas reveals that amplification of CNKSR3 is correlated with improved patient survival. *Am J Pathol*. 2013 Mar;182:678–687.